Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class ...

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.13. Operator: Good day, and thank you for ...

Department of Biochemistry, Medical College of Wisconsin, Milwaukee. (G.M.S., J.B., M.L., S.N.H., D.S.) Cardiovascular Center, Medical College of Wisconsin, Milwaukee ...

1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

1 Center for Clinical Pharmacology, Washington University School of Medicine in Saint Louis and University of Health Sciences and Pharmacy in Saint Louis, St. Louis, MO, United States 2 Department of ...

Introduction: Despite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as ...